< Weichung “Joe” Shih Ph.D. EOHSI Directory | EOHSI

A B C D E F G H I J K L M N O P R S T U W X Y Z

Weichung “Joe” Shih Ph.D.

Professor and Chair of Biostatistics Rutgers University, School of Public HealthEOHSI – Environmental Epidemiology and Statistics
Work School of Public Health Room 216 683 Hoes Lane Piscataway NJ 08840 Work Phone: 732-235-6791
Photo of Weichung “Joe” Shih Ph.D.

Biographical Info

Dr. Shih is a member of the Editorial Boards of the Society for Clinical Trials, the Journal of Statistics in Biopharmaceutical Research, Statistics in Medicine, Statistica Sinica, and the Journal of Clinical Cancer Research.

Research Areas

  • Biometrics
  • Bioinformatics
  • Statistics

Scholarly Activities

  • 2002 Excellence in Teaching Award, The Student Government Association, School of Public Health
  • 1996 Elected American Statistical Association (ASA) Fellow

Recent Publications

  1. McGuire, DK, Shih, WJ, Cosentino, F, Charbonnel, B, Cherney, DZI, Dagogo-Jack, S, Pratley, R, Greenberg, M, Wang, S, Huyck, S et al.. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2020; :. doi: 10.1001/jamacardio.2020.4511. PubMed PMID:33031522 PubMed Central PMC7542529
  2. Cosentino, F, Cannon, CP, Cherney, DZI, Masiukiewicz, U, Pratley, R, Dagogo Jack, S, Frederich, R, Charbonnel, B, Mancuso, J, Shih, WJ et al.. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020; :. doi: 10.1161/CIRCULATIONAHA.120.050255. PubMed PMID:33026243
  3. Cannon, CP, Pratley, R, Dagogo-Jack, S, Mancuso, J, Huyck, S, Masiukiewicz, U, Charbonnel, B, Frederich, R, Gallo, S, Cosentino, F et al.. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383 (15):1425-1435. doi: 10.1056/NEJMoa2004967. PubMed PMID:32966714
  4. Shih, WJ, Yao, C, Xie, T. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis. Ther Innov Regul Sci. 2020;54 (5):1236-1255. doi: 10.1007/s43441-020-00159-7. PubMed PMID:32865809 PubMed Central PMC7229886
  5. Krakora, R, Shih, W, Popli, P, Gorshein, E, Salaru, G, Moore, D, Chen, C, David, K, Bannerji, R. Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience. Clin Lymphoma Myeloma Leuk. 2020;20 (11):e890-e896. doi: 10.1016/j.clml.2020.06.010. PubMed PMID:32773302
  6. Silk, AW, Kaufman, HL, Curti, B, Mehnert, JM, Margolin, K, McDermott, D, Clark, J, Newman, J, Bommareddy, PK, Denzin, L et al.. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Front Oncol. 2019;9 :1483. doi: 10.3389/fonc.2019.01483. PubMed PMID:31998643 PubMed Central PMC6965158
  7. Lin, Y, Shih, WJ, Lu, SE. Two-stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers. Stat Med. 2019;38 (29):5445-5469. doi: 10.1002/sim.8370. PubMed PMID:31621944 PubMed Central PMC6842057
  8. Portal, DE, Weiss, RE, Wojtowicz, M, Mansour, A, Monken, C, Mehnert, JM, Aisner, JA, Kane, M, Nishioka, J, Aisner, S et al.. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. Cancer Gene Ther. 2020;27 (6):438-447. doi: 10.1038/s41417-019-0112-z. PubMed PMID:31222182 PubMed Central PMC6923616
  9. Shen, M, Jiang, YZ, Wei, Y, Ell, B, Sheng, X, Esposito, M, Kang, J, Hang, X, Zheng, H, Rowicki, M et al.. Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell. 2019;35 (1):64-80.e7. doi: 10.1016/j.ccell.2018.11.016. PubMed PMID:30612941
  10. Cannon, CP, McGuire, DK, Pratley, R, Dagogo-Jack, S, Mancuso, J, Huyck, S, Charbonnel, B, Shih, WJ, Gallo, S, Masiukiewicz, U et al.. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206 :11-23. doi: 10.1016/j.ahj.2018.08.016. PubMed PMID:30290289
Search PubMed
Categories: Faculty, Environmental Epidemiology and Statistics